{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:26:20Z","timestamp":1789248380152,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.rmed.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T08:32:37Z","timestamp":1487233957000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"125","author":[{"given":"Anthony","family":"D'Urzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rennard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejhandra","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Leselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.02.008_bib1","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2016"},{"issue":"99","key":"10.1016\/j.rmed.2017.02.008_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1183\/09059180.00009902","article-title":"Reducing cholinergic constriction: the major reversible mechanism in COPD","volume":"15","author":"Brusasco","year":"2006","journal-title":"Eur. Respir. Rev."},{"issue":"6","key":"10.1016\/j.rmed.2017.02.008_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1986.tb02956.x","article-title":"In\u00a0vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline","volume":"22","author":"Goldie","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.rmed.2017.02.008_bib4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/15412550903156333","article-title":"Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function","volume":"6","author":"Cazzola","year":"2009","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.rmed.2017.02.008_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","volume":"15","author":"D'Urzo","year":"2014","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2017.02.008_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.02.008_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"15","key":"10.1016\/j.rmed.2017.02.008_bib8","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.02.008_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1378\/chest.10-0865","article-title":"Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial","volume":"139","author":"Tashkin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.02.008_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","article-title":"Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD","volume":"116","author":"Donohue","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.02.008_bib11","series-title":"Duaklir\u00ae Genuair\u2122 (Aclidinium Bromide\/Formoterol Fumarate Dihydrate)","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.rmed.2017.02.008_bib12","series-title":"Ultibro\u00ae Breezhaler\u00ae","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.rmed.2017.02.008_bib13","series-title":"Anoro\u00ae Ellipta\u00ae","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.rmed.2017.02.008_bib14","series-title":"Anoro\u00ae Ellipta\u00ae","author":"Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.rmed.2017.02.008_bib15","series-title":"Health Canada Regulatory Decision Summary: DUAKLIR GENUAIR","author":"Canada","year":"2016"},{"key":"10.1016\/j.rmed.2017.02.008_bib16","series-title":"Public ARTG Summary BRIMICA GENUAIR 340\/12 Aclidinium Bromide and Eformoterol Fumarate Dihydrate Powder for Inhalation Dry Powder Inhaler","author":"Australian Register of Therapeutic Goods","year":"2016"},{"key":"10.1016\/j.rmed.2017.02.008_bib17","series-title":"Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials","author":"Hicks","year":"2014"},{"key":"10.1016\/j.rmed.2017.02.008_bib18","first-page":"475","article-title":"Evaluation of the psychometric properties of the nighttime symptoms of COPD instrument","volume":"10","author":"Mocarski","year":"2015","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"10.1016\/j.rmed.2017.02.008_bib19","unstructured":"A. Palsgrove, K. Houghton, A. Hareendran, M. Schaefer, J. Setyawan, M. Mocarski, et\u00a0al., The development of the Early Morning Symptoms of COPD Instrument (EMSCI)., Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual European Congress, Madrid, Spain, 5\u20138 November (2011)."},{"issue":"6","key":"10.1016\/j.rmed.2017.02.008_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1378\/chest.130.6.1695","article-title":"Pooled clinical trial analysis of tiotropium safety","volume":"130","author":"Kesten","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.02.008_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1465-9921-11-149","article-title":"Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents","volume":"11","author":"Tashkin","year":"2010","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.rmed.2017.02.008_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jaci.2006.07.002","article-title":"Adherence and persistence with fluticasone propionate\/salmeterol combination therapy","volume":"118","author":"Bender","year":"2006","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2017.02.008_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11096-008-9197-4","article-title":"Medication persistence among patients with asthma\/COPD drugs","volume":"30","author":"Haupt","year":"2008","journal-title":"Pharm. World Sci."},{"issue":"4","key":"10.1016\/j.rmed.2017.02.008_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/pds.1321","article-title":"Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions","volume":"16","author":"Krigsman","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"10.1016\/j.rmed.2017.02.008_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2007.00866.x","article-title":"Refill adherence by the elderly for asthma\/chronic obstructive pulmonary disease drugs dispensed over a 10-year period","volume":"32","author":"Krigsman","year":"2007","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2017.02.008_bib26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pds.1433","article-title":"Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma\/COPD medication","volume":"16","author":"Krigsman","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.rmed.2017.02.008_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/COPD.S14715","article-title":"Improving adherence with inhaler therapy in COPD","volume":"5","author":"Lareau","year":"2010","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2017.02.008_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3111\/13696998.2011.594123","article-title":"Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers","volume":"14","author":"Yu","year":"2011","journal-title":"J.\u00a0Med. Econ."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111730029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111730029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:35:28Z","timestamp":1760614528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461111730029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"alternative-id":["S095461111730029X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.02.008","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}